Infinitopes is at the forefront of cancer treatment innovation, focusing on the development of revolutionary cancer vaccines through its proprietary Infinitopes Precision Immunomics™ pipeline. This technology enables the reliable identification of highly-expressed and immunogenic tumor antigens presented by cancer cells, utilizing advanced laboratory techniques, computational methods, and machine learning workflows. The platform has demonstrated superior tumor protection in preclinical models compared to existing antigens, showcasing its potential for significant advancements in immuno-oncology. Infinitopes' vector platform, built on nearly a decade of immunology research, is designed to induce robust T cell immunity, ensuring both the magnitude and durability of the immune response.

The company's mission emphasizes the importance of timely intervention in cancer treatment, advocating for the initiation of vaccine administration at the earliest stages of a patient's journey. By integrating their innovative approach with conventional care, Infinitopes aims to enhance standard treatment protocols and optimize the effectiveness of vaccine therapies across diverse patient demographics. With a team of experts who have led numerous clinical trials in oncology, Infinitopes is poised to initiate its first-in-human trial in 2024, reflecting its commitment to transforming cancer care and improving patient outcomes globally.

United Kingdom

Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, developing vaccines for the treatment of cancer.

Infinitopes

Company Details